(Q39550679)

13 September 2017

title

The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice (English)

1 reference

13 September 2017

0 references

0 references

0 references

1 reference

Renee N Donahue

1

1 reference

13 September 2017

Patricia J McLaughlin

series ordinal

2

1 reference

13 September 2017

Ian S Zagon

series ordinal

3

1 reference

13 September 2017

language of work or name

English

0 references

publication date

30 April 2011

1 reference

13 September 2017

1 reference

13 September 2017

volume

122

1 reference

13 September 2017

issue

2

1 reference

13 September 2017

page(s)

382-388

1 reference

New therapies for ovarian cancer: cytotoxics and molecularly targeted agents

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

7 January 2021

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Alteration of cell-cycle regulation in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Modulation of human neuroblastoma transplanted into nude mice by endogenous opioid systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Production and characterization of polyclonal and monoclonal antibodies to the zeta (zeta) opioid receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Ontogeny of zeta (zeta), the opioid growth factor receptor, in the rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Opioids as modulators of cell death and survival--unraveling mechanisms and revealing new indications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Opioids and the apoptotic pathway in human cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Opioid growth factor modulates angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Differential effects of vascular growth factors on arterial and venous angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

First-line treatment of advanced ovarian cancer: current research and perspectives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Treatment of advanced pancreatic cancer with opioid growth factor: phase I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Low-dose naltrexone therapy improves active Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.009

10.1016/J.YGYNO.2011.04.009

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference